22 October 2024 The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).
The China subsidiary of French pharma major Sanofi on October 8 signed a strategic agreement with the Association of County Hospital President, a government -backed organization aiming to improve clinical practices in China’s rural areas, reports The Pharma Letter’s local correspondent Wang Fangqing. 11 October 2018
The three Japanese drugmakers that launched a program a year ago to discover new treatments using a drug-repositioning compound library have started a second recruitment round to find new researchers. 10 October 2018
Swedish startup Lobsor has won its first approval for Lecigon (levodopa/carbidopa/entacapone), a new therapeutic system for symptomatic treatment of advanced Parkinson’s disease, a decision which could shake up a market dominated by AbbVie. 10 October 2018
Shares in Affimed have fallen more than a quarter since the firm announced it was putting on hold development of AFM11, after the occurrence of Serious Adverse Events (SAEs) in three patients. 10 October 2018
The market value of US biopharma Trevena is worth just a third of its worth at Monday’s close after a US Food and Drug Administration (FDA) report raised concerns with its opioid injection to treat acute pain. 10 October 2018
Incoming Pfizer chief executive Albert Bourla is to stamp his mark firmly on the company’s leadership, as the firm announced a new executive team ready to clock on from the commencement of his tenure next year. 10 October 2018
American PARP inhibitor specialist Clovis Oncology will present four posters related to the Rubraca (rucaparib) development program at the 2018 European Society of Medical Oncology congress. 10 October 2018
Tokyo’s Eisai will provide clinical updates regarding its selective TKI Lenvima (lenvatinib), also marketed as Kisplyx, at the forthcoming annual meeting of the European Society for Medical Oncology (ESMO). 10 October 2018
The European Medicines Agency’s (EMA) Brexit preparedness business continuity plan (BCP) entered into its third phase on October 1, 2018, as announced at the beginning of August 2018. 10 October 2018
Zug, Switzerland-based oncology specialist Tesaro says it will present six abstracts at the upcoming annual meeting of the European Society for Medical Oncology (ESMO) in Munich, Germany. 10 October 2018
Ireland-headquartered generic and OTC drugmaker Perrigo, which recently said it was restructuring into two separate units, has announced the appointment of Murray Kessler as president, chief executive and member of the board of directors, effective immediately. 10 October 2018
The Russian government plans to provide access to imported drugs that have not undergone clinical trials within Russia, according to recent statements by some senior officials of the Russian Ministry of Health. 10 October 2018
Dr Martin Huber, chief medical officer of Tesaro, spoke with The Pharma Letter about his firm’s runner in the PARP blocker field, Zejula (niraparib). 9 October 2018
A leading British clinical research organization (CRO), Richmond Pharmacology, has published a detailed report criticizing current UK immigration policy and supporting proposals to install a skills-based migration system after Brexit. 9 October 2018
During the third quarter, pharmaceutical pricing dynamics remained under scrutiny. Specifically, regulators have highlighted the elimination of rebates as a way to protect consumers since patients' out-of-pocket expenses are influenced by the list, rather than net, price of each therapy. 9 October 2018
A final report from the Institute for Clinical and Economic Review (ICER) finds that the pricing of new therapies for the treatment of hereditary transthyretin amyloidosis (hATTR) “far exceeds commonly cited thresholds for cost effectiveness.” 8 October 2018
Over the past 24 months, the Latin American cannabis industry has emerged from the shadows to command the attention of the international cannabis community as over ten major markets have legalized medical cannabis. 8 October 2018
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. 21 October 2024
Trade group the Association of the British Pharmaceutical Industry (ABPI) has had its say on UK government plans to overhaul the National Health Service (NHS). 21 October 2024
Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain. 21 October 2024
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset. 21 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.